How to buy Rigel Pharmaceuticals stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rigel Pharmaceuticals stock

Own Rigel Pharmaceuticals stock in just a few minutes.

Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Rigel Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Rigel Pharmaceuticals. Find the stock by name or ticker symbol: RIGL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rigel Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rigel Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Rigel Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Rigel Pharmaceuticals share price

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$1.45 - USD$5.5
50-day moving average USD$3.7549
200-day moving average USD$3.3924
Wall St. target priceUSD$8.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.352

Buy Rigel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals financials

Revenue TTM USD$108.6 million
Gross profit TTM USD$47.6 million
Return on assets TTM -14.04%
Return on equity TTM -67.72%
Profit margin -27.38%
Book value $0.201
Market capitalisation USD$605.6 million

TTM: trailing 12 months

Shorting Rigel Pharmaceuticals shares

There are currently 22.0 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 30.6% up from 16.9 million last month.

There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.

Rigel Pharmaceuticals's "short interest ratio" (SIR)

Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 3.2 million). Rigel Pharmaceuticals's SIR currently stands at 6.98. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 6980 shares are currently held short.

However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1684% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 168 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Rigel Pharmaceuticals.

Find out more about how you can short Rigel Pharmaceuticals stock.

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:9 basis on 24 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $1.45 up to $5.5. A popular way to gauge a stock's volatility is its "beta".

RIGL.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.4721. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co. , Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site